Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

The advantages and disadvantages of CAR-T cell therapy should be carefully thought about for patients with melanoma.

Keytruda (pembrolizumab) is a brand-name solution for IV infusion prescribed to treat many types of cancer, including melanoma and lung cancer. As with other drugs, Keytruda can cause side effects ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

It will assess the safety, tolerability and initial efficacy of MB097 plus MSD’s (Merck & Co.) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with cutaneous melanoma who have not ...

Melanoma is a type of cancer that starts in cells called melanocytes, which produce the pigment melanin. There are several types of melanoma, and skin melanoma is the most common form. Melanocytes ...

Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress ...

1 CR and 2 PRs among 11 patients with cutaneous melanoma. SD in 6 patients including 3 with duration ... Cohort 3: 120 microgram/kg Q2W MDNA11 and 400 mg Q6W KEYTRUDA; Cohort 4: 120 microgram/kg Q3W ...

In partnership with Moderna MRNA, Merck is developing a personalized mRNA therapeutic cancer vaccine (V940/mRNA-4157) in combination with Keytruda for treating adjuvant melanoma and non-small cell ...